UCB SA (UCB.BR)
Exchange: BR
Currency: EUR
Price: 105.05 (Close)
Summary
| 52 Week range | 200d Moving Avg. | Beta |
| 74.32 – 107.40 | 94.93 | 0.42 |
| Dividend | Dividend Yield | Ex-Dividend date |
| 1.27 | 1.21% | 2021-04-30 |
| P/E Ratio | Latest EPS | DGR 3 years |
| 19.26 | 5.46 | 2.48% |
Undervalued
Low
Very low Volatility
High
Slow
Dividend Growth
Fast
Profile
UCB SA, a biopharmaceutical company, develops therapies and solutions for people with neurology and immunology diseases in the United States, Europe, and internationally. The company’s primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn’s disease, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson’s disease and restless legs syndrome; and Nayzilam, a nasal spray rescue treatment for seizure clusters. It also provides Zyrtec and Xyzal for allergies; Nootropil for memory problems; and Xyrem for narcolepsy. In addition, the company offers Evenity for the treatment of osteoporosis; bimekizumab for treating psoriasis, psoriatic arthritis, and axial spondyloarthritis; and dapirolizumab pegol for systemic lupus erythematosus. Further, it is involved in developing padsevonil for the treatment of drug-resistant epilepsy; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; UCB7858 for immunology; and UCB0599 for neurology; and UCB0107 for progressive supranuclear palsy. Additionally, the company engages in contract manufacturing activities. It has a multi-year collaboration agreement with Stanford Medicine to enhance patient value for people living with severe diseases. UCB SA has collaboration agreements with Sanofi, Amgen, Biogen, Otsuka, and doc.ai. The company was founded in 1928 and is headquartered in Brussels, Belgium.
| Sector: | Industry: | |
| Healthcare | Biotechnology | |
Total ESG Score
0 – 0 percentile
Environment
0 – 0 percentile
Social
0 – 0 percentile
Governance
0 – 0 percentile
Controversy level
0
MSCI ESG-Rating
n.a.
see MSCI ESG rating explained
Dividend Safety Metrics
| Latest EPS | 5.46 | |
| Annual Payout | 1.27 | |
| Payout Ratio | 23.26% | |
| Dividend growth | 11 Years | |
| Dividend Score | 0 | |
| Dividend Coverage Ratio | 4.30 | |
| Altman-Z score | 0.00 |
UCB SA (UCB.BR) Valuation
UCB SA’s current dividend yield of 1.21% is 10% above its 5-year average. The 5-year average dividend yield is 1.10% (see red-line in chart). This indicates the stock may be undervalued today.
UCB SA (UCB.BR) Performance
The chart below displays the total price return(%) of UCB SA for different periods:
UCB SA (UCB.BR) Total Return
The chart below displays the (CAGR) total return (%) including all dividends paid of UCB SA for different periods:
Dividend Scorecard
| Dividend Yield (TTM) | Annual Payout | Payout Ratio | Dividend growth |
| 1.21 | 1.27 | 23.26% | 11 Years |
Dividend Growth Summary
| 3 Year Growth Rate (CAGR) | 2.48% |
| 5 Year Growth Rate (CAGR) | 2.06% |
| 10 Year Growth Rate (CAGR) | 1.92% |
Dividend Growth Rates History
| Year | Payout Amount | Annual Payout Growth (YoY) |
|---|---|---|
| 2021 | 0.889 | 2.4% |
| 2020 | 0.868 | 2.5% |
| 2019 | 0.847 | 2.5% |
| 2018 | 0.826 | 2.6% |
| 2017 | 0.805 | 0.2% |
| 2016 | 0.803 | 1.0% |
| 2015 | 0.795 | 1.9% |
| 2014 | 0.780 | 2.0% |
| 2013 | 0.765 | 2.0% |
| 2012 | 0.750 | 2.0% |
| 2011 | 0.735 | 2.1% |
| 2010 | 0.720 | 4.3% |
| 2009 | 0.690 | 0.0% |
| 2008 | 0.690 | 2.2% |
UCB SA (UCB.BR) Dividend Payment History